CELLPHIRE, INC

ROCKVILLE, MD · Biotech · Private

shelf-stable platelet product for hemorrhage control

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cellphire.com

Sector: Biotech
Headquarters: ROCKVILLE, MD
Latest Form D: $3M, Dec 2025
Total capital: $167M

Federal grants: $150K; 1 award · 2017; Rank in peer group#4 of 54
Private capital raised: $5M; 2 Form D · last Dec 2025; 10 months since last filing
Federal contracts: $162M; 7 awards · Defense, Health and Human S; Rank in Biotech#8 of 4373
Granted patents: 14; 26 pending · first 2022; Rank in peer group#5 of 54

Capital timeline

Latest events

Dec 2025Private capital raisedForm D · SEC · 2nd filing$3M
Oct 2023Private capital raisedForm D · SEC · 1st filing$2M
Sep 2020Federal contractDefense · Lyophilized Canine Plasma Sequential Phase II$473K
Dec 2019Federal contractDefense · Cryopreserved Platelet (cpp) Development For US Fda Licensure$70.3M
Sep 2018Federal contractDefense · Freeze Dried Plasma For Canines$999K
Jan 2017Federal grantDefense · Phase I · Freeze Dried Plasma for Canines$150K
Sep 2013Federal contractHealth and Human S · Igf::ot::igf For Other Functionscellphire$86.1M

Show 3 earlier federal awards

Mar 2010Federal contractDefense · Apheresis Pools$42K
Jul 2007Federal contractDefense · Basic Contract Award$2.5M
Jun 2005Federal contractDefense$1.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

220months

from CELLPHIRE, INC’s first federal award to its first private round.

First federal award · Jun 2005: Defense · $1.8M
First Form D · Oct 2023: $2M · 1st Form D
Awards before first raise: 8 awards

An association in public records, not a cause or a prediction.

Standing among 54 peers

Line = median

Biotech · Material

Federal grants#4 · top 7%
Granted patents#5 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Angela HowertonExecutive OfficerNamed in SEC Form D filings
Cristiane WolfeExecutive OfficerNamed in SEC Form D filings
David HirshDirectorNamed in SEC Form D filings
Derek WoodsDirectorNamed in SEC Form D filings
James PeakeDirectorNamed in SEC Form D filings
Michael GaffneyExecutive Officer, DirectorNamed in SEC Form D filings

Show all 11 people

Pamela ConleyDirectorNamed in SEC Form D filings
Rafael JordaDirectorNamed in SEC Form D filings
Randall StanickyDirectorNamed in SEC Form D filings
Rob WoodsExecutive OfficerNamed in SEC Form D filings
Thomas DubinDirectorNamed in SEC Form D filings

What it has protected

USPTO · 14 granted of 40

Aug 13, 2026PendingFrozen Activated Platelet Compositions And Collections, And Methods Of Making And Using The SameUSPTOApplication 19402977
Aug 11, 2026GrantedPlatelet Derivative Compositions, And Methods Of Making And Using Such CompositionsUSPTOUS 12,702,682
Jun 25, 2026PendingFrozen Activated Platelet Compositions And Collections, And Methods Of Making And Using The SameUSPTOApplication 19402962

Show all 40 patent records

Frozen Activated Platelet Compositions And Collections, And Methods Of Making And Using The SameAug 13, 2026 · Application 19402977Pending
Platelet Derivative Compositions, And Methods Of Making And Using Such CompositionsAug 11, 2026 · US 12,702,682Granted
Frozen Activated Platelet Compositions And Collections, And Methods Of Making And Using The SameJun 25, 2026 · Application 19402962Pending
Platelet Derivative Compositions In The Form Of A PowderOct 2, 2025 · Application 19234179Pending
Thrombosomes As An Antiplatelet Agent Reversal AgentSep 23, 2025 · US 12,419,914Granted
Platelets As Delivery AgentsAug 5, 2025 · US 12,378,523Granted
Platelet Derivative Compositions, And Pluralities Of Containers Containing SameJul 29, 2025 · US 12,370,219Granted
Methods For Administering Freeze-dried Platelet Derivative Compositions To Subjects Treated With A Factor Xi InhibitorJun 5, 2025 · Application 19053371Pending
Methods Using Freeze-dried Platelet Derivative Compositions For Restoring Hemostasis In A SubjectMay 13, 2025 · US 12,295,972Granted
Treatment Of Von Willebrand DiseaseMay 6, 2025 · US 12,290,532Granted
Methods Of Administering Platelet Derivative Compositions To Reduce Bleeding In Subjects Refractory To Platelet TransfusionMar 6, 2025 · Application 18949648Pending
Methods For Administering Platelet Derivative Compositions To Subjects Afflicted With Hermansky Pudlak Syndrome Or Bernard Soulier SyndromeFeb 27, 2025 · Application 18943815Pending
Mri-agent Loaded Platelet Compositions And Methods Of Preparing And Using The SameFeb 27, 2025 · Application 18943861Pending
Methods Of Treating Bleeding In A Subject Treated With An Antiplatelet AgentJan 28, 2025 · US 12,208,122Granted
Methods For Preparing And Administering Cryopreserved Platelets And Platelet Derivatives Loaded With Anti-cancer DrugsJan 2, 2025 · Application 18737851Pending
Methods For Controlling Bleeding In A Subject Afflicted With Hermansky Pudlak Syndrome Using Platelet Derivative CompositionsSep 19, 2024 · Application 18653905Pending
Platelet Diagnostic Imaging AgentsAug 1, 2024 · Application 18629638Pending
Platelets Loaded With Anti-cancer AgentsApr 23, 2024 · US 11,965,178Granted
Platelet Derivatives For Treating CoagulopathyFeb 29, 2024 · Application 18504080Pending
Treatment Of Von Willebrand DiseaseFeb 20, 2024 · US 11,903,971Granted
Materials And Methods For Producing Blood ProductsNov 14, 2023 · US 11,813,572Granted
Materials And Methods For Producing Blood ProductsNov 9, 2023 · Application 18341700Pending
Blood Plasma-containing CompositionsNov 2, 2023 · Application 18347535Pending
Platelets As Delivery AgentsSep 26, 2023 · US 11,767,511Granted
Materials And Methods For Producing Blood ProductsSep 12, 2023 · US 11,752,468Granted
Platelets Loaded With Anti-cancer AgentsAug 10, 2023 · Application 18297581Pending
Products And Methods Using A Platelet-derived Hemostatic Agent For Controlling Bleeding And Improving HealingAug 10, 2023 · Application 18301946Pending
Thrombosomes As An Antiplatelet Agent Reversal AgentJul 18, 2023 · US 11,701,388Granted
Platelet Derived Extracellular VesiclesMay 18, 2023 · Application 18055767Pending
Canine Blood Platelet PreparationsApr 13, 2023 · Application 18061359Pending
Materials And Methods For Producing Blood ProductsDec 20, 2022 · US 11,529,587Granted
Freeze-dried Platelet Derivative Compositions For Treating Anticoagulant-induced CoagulopathySep 8, 2022 · Application 17674831Pending
Freeze-dried Platelet Derivative Compositions For Treating Antiplatelet Induced CoagulopathySep 1, 2022 · Application 17674770Pending
Freeze-dried Peripheral Blood Mononuclear Cell Compositions And MethodsJul 7, 2022 · Application 17523722Pending
Freeze-dried Platelet Derivative Compositions For Treating Antiplatelet-induced CoagulopathyJun 2, 2022 · Application 17673773Pending
Nucleated Cell Preservation By LyophilizationDec 2, 2021 · Application 17401474Pending
Blood Plasma-containing CompositionsNov 18, 2021 · Application 17385632Pending
Anti-fibrinolytic Loaded PlateletsOct 7, 2021 · Application 17166487Pending
Methods Of Treating Acquired Hemophilia With Anti-fibrinolytic Loaded PlateletsOct 7, 2021 · Application 17166648Pending
Methods Of Treating Congenital Hemophilia With Anti-fibrinolytic Loaded PlateletsSep 30, 2021 · Application 17166605Pending

Ginkgo BioworksSimilar federal contract value in Biotech · $191M in contracts
Cellerant Therapeutics, Inc.Similar federal contract value in Biotech · $185M in contracts
Sarepta TherapeuticsSimilar federal contract value in Biotech · $169M in contracts
VEDANTA BIOSCIENCES, INC.Similar federal contract value in Biotech · $99.1M in contracts
CONTINUUS Pharmaceuticals, Inc.Similar federal contract value in Biotech · $73.7M in contracts
GUILD ASSOCIATES INCSimilar federal contract value in Biotech · $69.6M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.